Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer

BioMed Research International

Volumn 2018, Issue , 2018, Pages

  Pellati, Federica ^a   Borgonetti, Vittoria ^b   Brighenti, Virginia ^a   Biagi, Marco ^b   Benvenuti, Stefania ^a   Corsi, Lorenzo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANNABINOID; CANNABIS; CYCLOOXYGENASE 2; ENDOCANNABINOID; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 2; ANTIOXIDANT;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER MODEL; CANCER PAIN; CANCER RADIOTHERAPY; CANNABIS SATIVA; CELL PROLIFERATION; DRUG MECHANISM; HUMAN; INFLAMMATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; ONCOGENE C FOS; OXIDATIVE STRESS; REVIEW; THERAPY EFFECT; ANIMAL; CHEMISTRY; DRUG EFFECT;

ANIMALS; ANTIOXIDANTS; CANNABINOIDS; CANNABIS; HUMANS; OXIDATIVE STRESS;

EID: 85058952952     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2018/1691428     Document Type: Review

References (137)

1. J. A. Hartsel, J. Eades, B. Hickory, and A. Makriyannis, "Cannabis sativa andHemp, " Nutraceuticals: Efficacy, Safety and Toxicity, pp. 735-754, 2016.
2. C. M. Andre, J. Hausman, and G. Guerriero, "Cannabis sativa: The Plant of the Thousand and One Molecules, " Frontiers in Plant Science, vol. 7, 2016.
3. G. Appendino, G. Chianese, and O. Taglialatela-Scafati, "Cannabinoids: Occurrence and medicinal chemistry, " Current Medicinal Chemistry, vol. 18, no. 7, pp. 1085-1099, 2011.
4. B. F. Thomas and M. A. ElSohly, "The analytical chemistry of Cannabis: quality assessment, assurance and regulation of medicinal marijuana and cannabinoid preparations, " Elsevier, Amsterdam, 1st edition, 2015.
5. "European Commission, Food safety, plant variety catalogues, databases and information systems, " 2018, https://ec.europa.eu/food/plant/plantpropagation.material/plantvariety.catalogues.databases.en.
6. L. O. Hanus, S. M. Meyer, E. Muñoz, O. Taglialatela-Scafati, and G. Appendino, "Phytocannabinoids: A unified critical inventory, " Natural Product Reports, vol. 33, no. 12, pp. 1357-1392, 2016.
7. V. Brighenti, F. Pellati, M. Steinbach, D. Maran, and S. Benvenuti, "Development of a new extraction technique andHPLC method for the analysis of non-psychoactive cannabinoids in fibre-TypeCannabis sativa L. (hemp), " Journal of Pharmaceutical and Biomedical Analysis, vol. 143, pp. 228-236, 2017.
8. F. Pellati, V. Brighenti, J. Sperlea, L. Marchetti, D. Bertelli, and S. Benvenuti, "NewMethods for theComprehensive Analysis of Bioactive Compounds in Cannabis sativa L. (hemp), "Molecules, vol. 23, no. 10, 2018.
9. M. A. ElSohly and D. Slade, "Chemical constituents of marijuana: The complex mixture of natural cannabinoids, " Life Sciences, vol. 78, no. 5, pp. 539-548, 2005.
10. B. De Backer, B. Debrus, P. Lebrun et al., "Innovative development and validation of an HPLC/DAD method for the qualitative and quantitative determination of major cannabinoids in cannabis plant material, " Journal of Chromatography B, vol. 877, no. 32, pp. 4115-4124, 2009.
11. A. A. Izzo, F. Borrelli, R. Capasso, V. Di Marzo, and R. Mechoulam, "Non-psychotropic plant cannabinoids: new therapeutic opportunities froman ancient herb, " Trends in Pharmacological Sciences, vol. 30, no. 10, pp. 515-527, 2009.
12. J. Ferńandez-Ruiz, M. Moreno-Martet, C. Rodŕiguez-Cueto et al., "Prospects for cannabinoid therapies in basal ganglia disorders, " British Journal of Pharmacology, vol. 163, no. 7, pp. 1365-1378, 2011.
13. S. P. H. Alexander, "Therapeutic potential of cannabis-related drugs, " Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 64, pp. 157-166, 2016.
14. A. C. Campos, M. V. Fogaça, A. B. Sonego, and F. S. Guimarães, "Cannabidiol, neuroprotection and neuropsychiatric disorders, " Pharmacological Research, vol. 112, pp. 119-127, 2016.
15. R. Brenneisen, "Chemistry and analysis of phytocannabinoids and other Cannabis constituents, " in Marijuana and the Cannabinoids, M. A. ElSohly, Ed., 49, p. 17, Marijuana and the cannabinoids, Humana Press Inc., Totowa, NJ, USA, 2007.
16. S. Pisanti, A.M. Malfitano, E. Ciaglia et al., "Cannabidiol: State of the art and new challenges for therapeutic applications, " Pharmacology &Therapeutics, vol. 175, pp. 133-150, 2017.
17. F. Pollastro, A. Minassi, and L. G. Fresu, "Cannabis Phenolics and their Bioactivities, " Current Medicinal Chemistry, vol. 25, no. 10, pp. 1160-1185, 2018.
18. O. Werz, J. Seegers, A. M. Schaible et al., "Cannflavins from hemp sprouts, a novel cannabinoid-free hemp food product, target microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase, " PharmaNutrition, vol. 2, no. 3, pp. 53-60, 2014.
19. G. Allegrone, F. Pollastro, G. Magagnini et al., "The Bibenzyl Canniprene Inhibits the Production of Pro-Inflammatory Eicosanoids and Selectively Accumulates in Some Cannabis sativa Strains, " Journal of Natural Products, vol. 80, no. 3, pp. 731-734, 2017.
20. S. I. Grivennikov, F. R. Greten, and M. Karin, "Immunity, Inflammation, and Cancer, " Cell, vol. 140, no. 6, pp. 883-899, 2010.
21. D. Namdar and H. Koltai, "Medical Cannabis for the treatment of inflammation, " Nat. Prod. Commun, vol. 13, pp. 249-254, 2018.
22. K. Mackie and N. Stella, "Cannabinoid receptors and endocannabinoids: evidence for newplayers, "The AAPS Journal, vol. 8, no. 2, article 34, pp. E298-E306, 2006.
23. L. Jean-Gilles, M. Braitch, M. L. Latif et al., "Effects of proinflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells, " Acta Physiol, vol. 214, pp. 63-74, 2015.
24. K. Fijal and M. Filip, "Clinical/therapeutic approaches for cannabinoid ligands in central and peripheral nervous system diseases: Mini review, " Clinical Neuropharmacology, vol. 39, no. 2, pp. 94-101, 2016.
25. K. L. Mccoy, "Interaction between Cannabinoid System and Toll-Like Receptors Controls Inflammation, " Mediators of Inflammation, vol. 2016, Article ID 5831315, 18 pages, 2016.
26. P. Nagarkatti, R. Pandey, S. A. Rieder, V. L. Hegde, and M. Nagarkatti, "Cannabinoids as novel anti-inflammatory drugs, " Future Medicinal Chemistry, vol. 1, no. 7, pp. 1333-1349, 2009.
27. S. Burstein, "Cannabidiol (CBD) and its analogs: A review of their effects on inflammation, " Bioorganic & Medicinal Chemistry, vol. 23, no. 7, pp. 1377-1385, 2015.
28. J. M. Jamontt, A. Molleman, R. G. Pertwee, and M. E. Parsons, "The effects of .9-Tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis, " British Journal of Pharmacology, vol. 160, no. 3, pp. 712-723, 2010.
29. D. de Filippis, G. Esposito, C. Cirillo et al., "Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis, " PLoS ONE, vol. 6, no. 12, 2011.
30. J. M. Sido, A. R. Jackson, P. S. Nagarkatti, and M. Nagarkatti, "Marijuana-derived .-9-Tetrahydrocannabinol suppresses Th1/Th17 cell-mediated delayed-Type hypersensitivity through microRNA regulation, " Journal of Molecular Medicine, vol. 94, no. 9, pp. 1039-1051, 2016.
31. E. Berdyshev, E. Boichot, M. Corbel, N. Germain, and V. Lagente, "Effects of cannabinoid receptor ligands on LPSinduced pulmonary inflammation in mice, " Life Sciences, vol. 63, no. 8, pp. 125-129, 1998.
32. M. D. Roth, J. T. Castaneda, and S. M. Kiertscher, "Exposure to .9-Tetrahydrocannabinol impairs the differentiation of human monocyte-derived dendritic cells and their capacity for T cell activation, " Journal of Neuroimmune Pharmacology, vol. 10, no. 2, pp. 333-343, 2015.
33. T. Ngaotepprutaram, B. L. Kaplan, and N. E. Kaminski, "Impaired NFAT and NF.B activation are involved in suppression of CD40 ligand expression by .9-Tetrahydrocannabinol in human CD4+ T cells, " Toxicology and Applied Pharmacology, vol. 273, no. 1, pp. 209-218, 2013.
34. Y.-H. Chang, S. T. Lee, and W.-W. Lin, "Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids, " Journal of Cellular Biochemistry, vol. 81, no. 4, pp. 715-723, 2001.
35. L. R. Ruhaak, J. Felth, P. C. Karlsson, J. J. Rafter, R. Verpoorte, and L. Bohlin, "Evaluation of the cyclooxygenase inhibiting effects of sixmajor cannabinoids isolated fromCannabis sativa, " Biological &Pharmaceutical Bulletin, vol. 34, no. 5, pp. 774-778, 2011.
36. S. C. Shivers, C. Newton, H. Friedman, and T. W. Klein, ".9-Tetrahydrocannabinol (THC)modulates IL-1 bioactivity in human monocyte/macrophage cell lines, " Life Sciences, vol. 54, no. 17, pp. 1281-1289, 1994.
37. C. Lombard, M. Nagarkatti, and P. S. Nagarkatti, "Targeting cannabinoid receptors to treat leukemia: Role of cross-Talk between extrinsic and intrinsic pathways in 9-Tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells, " Leukemia Research, vol. 29, no. 8, pp. 915-922, 2005.
38. W. Jia, V. L. Hegde, N. P. Singh et al., ".9-Tetrahydrocannabinolinduced apoptosis in Jurkat leukemia T cells is regulated by translocation of bad to mitochondria, " Molecular Cancer Research, vol. 4, no. 8, pp. 549-562, 2006.
39. B. Costa, M. Colleoni, S. Conti et al., "Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw, " Naunyn-Schmiedebergs Archives of Pharmacology, vol. 369, no. 3, pp. 294-299, 2004.
40. S. Takeda, H. Okazaki, E. Ikeda et al., "Down-regulation of cyclooxygenase-2 (cox-2) by cannabidiolic acid in human breast cancer cells, " Journal of Toxicological Sciences, vol. 39, no. 5, pp. 711-716, 2014.
41. S. Ben-Shabat, L. O. Hanu.s, G. Katzavian, and R. Gallily, "New cannabidiol derivatives: Synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity, " Journal ofMedicinal Chemistry, vol. 49, no. 3, pp. 1113-1117, 2006.
42. B. Watzl, P. Scuderi, and R. R. Watson, "Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro, " International Journal of Immunopharmacology, vol. 13, no. 8, pp. 1091-1097, 1991.
43. S. Petrosino, R. Verde, M. Vaia, M. Allara, T. Iuvone, and V. Di Marzo, "Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis, "The Journal of Pharmacology and Experimental Therapeutics, vol. 365, no. 3, pp. 652-663, 2018.
44. F. Borrelli, I. Fasolino, B. Romano et al., "Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease, " Biochemical Pharmacology, vol. 85, no. 9, pp. 1306-1316, 2013.
45. A. A. Izzo, R. Capasso, G. Aviello et al., "Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility inmice, " British Journal of Pharmacology, vol. 166, no. 4, pp. 1444-1460, 2012.
46. M. L. Barrett, D. Gordon, and F. J. Evans, "Isolation from cannabis sativa L. of cannflavin-A novel inhibitor of prostaglandin production, " Biochemical Pharmacology, vol. 34, no. 11, pp. 2019-2024, 1985.
47. W.-J. Yoon, N. H. Lee, and C.-G. Hyun, "Limonene suppresses lipopolysaccharide-induced production of nitric oxide, prostaglandin E2, and pro-inflammatory cytokines in RAW 264.7 macrophages, " Journal of Oleo Science, vol. 59, no. 8, pp. 415-421, 2010.
48. J. Gertsch, M. Leonti, S. Raduner et al., "Beta-caryophyllene is a dietary cannabinoid, " Proceedings of the National Acadamy of Sciences of the United States of America, vol. 105, no. 26, pp. 9099-9104, 2008.
49. N. V. DiPatrizio, "Endocannabinoids in the Gut, " Cannabis and Cannabinoid Research, vol. 1, no. 1, pp. 67-77, 2016.
50. A. Alhamoruni, A. C. Lee, K. L. Wright, M. Larvin, and S. E. OSullivan, "Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability, " The Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 1, pp. 92-102, 2010.
51. A. Alhamoruni, K. L. Wright, M. Larvin, and S. E. OSullivan, "Cannabinoids mediate opposing effects on inflammationinduced intestinal permeability, " British Journal of Pharmacology, vol. 165, no. 8, pp. 2598-2610, 2012.
52. D. G. Couch, C. Tasker, E. Theophilidou, J. N. Lund, and S. E. OSullivan, "Cannabidiol and palmitoylethanolamide are antiinflammatory in the acutely inflamed human colon, " Clinical Science, vol. 131, no. 21, pp. 2611-2626, 2017.
53. S. Gigli, L. Seguella, M. Pesce et al., "Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco-2 cells, " United European Gastroenterology Journal, vol. 5, no. 8, pp. 1108-1115, 2017.
54. R.-V. Kalaydina, B. Qorri, and M. R. Szewczuk, "Preventing negative shifts in gut microbiota with Cannabis therapy: implications for colorectal cancer, " Adv. Res. Gastroentero. Hepatol, vol. 7, pp. 1-5, 2017.
55. K. Mackie, Y. Lai, R. Westenbroek, and R. Mitchell, "Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-Type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor, " The Journal of Neuroscience, vol. 15, no. 10, pp. 6552-6561, 1995.
56. K. Maresz, G. Pryce, E.D. Ponomarev et al., "Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells, " Nature Medicine, vol. 13, no. 4, pp. 492-497, 2007.
57. T. W. Klein, B. Lane, C. A. Newton, and H. Friedman, "The cannabinoid system and cytokine network, " Proceedings of the Society for Experimental Biology and Medicine, vol. 225, no. 1, pp. 1-8, 2000.
58. L. Thors, A. Bergh, E. Persson et al., "Fatty acid amide hydrolase in prostate cancer: Association with disease severity and outcome, CB1 receptor expression and regulation by IL-4, " PLoS ONE, vol. 5, no. 8, Article ID e12275, 2010.
59. M. Maccarrone, H. Valensise, M. Bari, N. Lazzarin, C. Romanini, and A. Finazzi-Agro, "Progesterone up-regulates anandamide hydrolase in human lymphocytes: Role of cytokines and implications for fertility, " The Journal of Immunology, vol. 166, no. 12, pp. 7183-7189, 2001.
60. A. Rubio-Araiz, A. Aŕevalo-Martin, O. Gomez-Torres et al., "The endocannabinoid system modulates a transient TNF pathway that induces neural stem cell proliferation, " Molecular and Cellular Neuroscience, vol. 38, no. 3, pp. 374-380, 2008.
61. M. Rajesh, P. Mukhopadhyay, S. Batkai et al., "CB2-receptor stimulation attenuates TNF-.-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 293, no. 4, pp. H2210-H2218, 2007.
62. S. Vivekanantham, S. Shah, R. Dewji, A. Dewji, C. Khatri, and R. Ologunde, "Neuroinflammation in Parkinsons disease: Role in neurodegeneration and tissue repair, " International Journal of Neuroscience, vol. 125, no. 10, pp. 717-725, 2015.
63. T. Koudriavtseva and C. Mainero, "Neuroinflammation, neurodegeneration and regeneration in multiple sclerosis: Intercorrelated manifestations of the immune response, " Neural Regeneration Research, vol. 11, no. 11, pp. 1727-1730, 2016.
64. R. Gordon and T. M. Woodruff, "Neuroinflammation as a therapeutic target in neurodegenerative diseases, " in Diseasemodifying targets in neurodegenerative disorders, V. Baekelandt and E. Lobbestael, Eds., pp. 49-80, Academic Press, Cambridge, 2017.
65. M. T. Heneka, M. J. Carson, J. El. Khoury et al., "Neuroinflammation in Alzheimers disease, " The Lancet Neurology, vol. 14, no. 4, pp. 388-405, 2015.
66. Geraldine Gelders, Veerle Baekelandt, and Anke Van der Perren, "Linking Neuroinflammation and Neurodegeneration in Parkinsons Disease, " Journal of Immunology Research, vol. 2018, Article ID 4784268, 12 pages, 2018.
67. E. C. Hirsch, S. Vyas, and S. Hunot, "Neuroinflammation in Parkinsons disease, " Parkinsonism & Related Disorders, vol. 18, no. 1, pp. S210-S212, 2012.
68. T. Chitnis, "The Role of CD4 T Cells in the Pathogenesis of Multiple Sclerosis, " International Review of Neurobiology, vol. 79, pp. 43-72, 2007.
69. B. J. Kaskow and C. Baecher-Allan, "Effector T Cells inMultiple Sclerosis, " Cold Spring Harbor Perspectives in Medicine, vol. 8, no. 4, p. a029025, 2018.
70. V. Borgonetti, P. Governa, M. Montopoli, and M. Biagi, "Cannabis sativa L. constituents and their role in neuroinflammation, " Curr. Bioact. Compd, 2018.
71. E. Janefjord, J. L. V. Maag, B. S. Harvey, and S. D. Smid, "Cannabinoid effects on amyloid fibril and aggregate formation, neuronal and microglial-Activated neurotoxicity in vitro, " Cellular and Molecular Neurobiology, vol. 34, no. 1, pp. 31-42, 2014.
72. E. Kozela, M. Pietr, A. Juknat, N. Rimmerman, R. Levy, and Z. Vogel, "Cannabinoids delta(9)-Tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-Activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells, " The Journal of Biological Chemistry, vol. 285, no. 3, pp. 1616-1626, 2010.
73. S. A. Hunter and S. H. Burstein, "Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis, " Life Sciences, vol. 60, no. 18, pp. 1563-1573, 1997.
74. M. Solinas, P. Massi, V. Cinquina et al., "Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect, " PLoS ONE, vol. 8, no. 10, Article IDe76918, 2013.
75. A. M. Mart?n-Moreno, D. Reigada, B. G. Ram?rez et al., "Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to alzheimers disease, " Molecular Pharmacology, vol. 79, no. 6, pp. 964-973, 2011.
76. G. Esposito, C. Scuderi, M. Valenza et al., "Cannabidiol reduces A-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR involvement, " PLoS ONE, vol. 6, no. 12, Article ID e28668, 2011.
77. S. Dirikoc, S. A. Priola, M. Marella, N. Zsurger, and J. Chabry, "Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity, " The Journal of Neuroscience, vol. 27, no. 36, pp. 9537-9544, 2007.
78. L. Corsi, F. Pellati, V. Brighenti, N. Plessi, and S. Benvenuti, "Chemical composition and in vitro neuroprotective activity of fibre-Type Cannabis sativa L. (hemp), " Current Bioactive Compounds, vol. 14, 2018.
79. A. Gugliandolo, F. Pollastro, G. Grassi, P. Bramanti, and E. Mazzon, "In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid, " International Journal of Molecular Sciences, vol. 19, no. 7, article E1992, 2018.
80. K. Guo, X. Mou, J. Huang, N. Xiong, and H. Li, "Transcaryophyllene suppresses hypoxia-induced neuroinflammatory responses by inhibiting NF-B activation in microglia, " Journal of Molecular Neuroscience, vol. 54, no. 1, pp. 41-48, 2014.
81. G. Watt and T. Karl, "In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimers Disease, " Front. Pharmacol, vol. 8, article 20, 2017.
82. C. Scuderi, L. Steardo, and G. Esposito, "Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPAR involvement, " Phytotherapy Research, vol. 28, no. 7, pp. 1007-1013, 2014.
83. B. Hughes and C. E. Herron, "Cannabidiol Reverses Deficits in Hippocampal LTP in a Model of Alzheimers Disease, " Neurochemical Research, 2018.
84. K. Kundu and Y. J. Surh, "Inflammation: gearing the journey to cancer, " Mutat. Res, vol. 659, pp. 15-30, 2008.
85. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, "Cancerrelated inflammation, " Nature, vol. 454, no. 7203, pp. 436-444, 2008.
86. H. F. Dvorak, "Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing, " The New England Journal ofMedicine, vol. 315, no. 26, pp. 1650-1659, 1986.
87. S. M. Crusz and F. R. Balkwill, "Inflammation and cancer: Advances and new agents, " Nature Reviews Clinical Oncology, vol. 12, pp. 584-596, 2015.
88. S. I. Grivennikov and M. Karin, "Inflammation and oncogenesis: A vicious connection, " Curr. Opin. Genet. Dev, vol. 20, pp. 65-71, 2010.
89. K. Tanaka, I. Babic, D. Nathanson et al., "Oncogenic EGFR signaling activates an mTORC2-NF-B pathway that promotes chemotherapy resistance, " Cancer Discovery, vol. 1, no. 6, pp. 524-538, 2011.
90. C. Berasain, M. J. Perugorria, M.U. Latasa et al., "The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer, " Experimental Biology and Medicine, vol. 234, no. 7, pp. 713-725, 2009.
91. M. Elbaz, M. W. Nasser, J. Ravi et al., "Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-Tumor mechanisms of Cannabidiol in breast cancer, "Molecular Oncology, vol. 9, no. 4, pp. 906-919, 2015.
92. V. Chiurchiu, M. Lanuti, M. De Bardi, L. Battistini, and M. Maccarrone, "The differential characterization of GPR55 receptor in human peripheral blood reveals a distinctive expression in monocytes and NK cells and a proinflammatory role in these innate cells, " International Immunology, vol. 27, no. 3, pp. 153-160, 2015.
93. D. Wang, H. Wang, W. Ning, M. G. Backlund, S. K. Dey, and R. N. DuBois, "Loss of cannabinoid receptor 1 accelerates intestinal tumor growth, " Cancer Research, vol. 68, no. 15, pp. 6468-6476, 2008.
94. B. Mukhopadhyay, K. Schuebel, P. Mukhopadhyay et al., "Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression throughmultiple mechanisms, " Hepatology, vol. 61, no. 5, pp. 1615-1626, 2015.
95. A. H. Benz, C. Renne, E. Maronde et al., "Expression and functional relevance of cannabinoid receptor 1 in hodgkin lymphoma, " PLoS ONE, vol. 8, no. 12, Article ID e81675, 2013.
96. E. M. Messalli, F. Grauso, R. Luise, A. Angelini, and R. Rossiello, "Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors, " American Journal of Obstetrics & Gynecology, vol. 211, no. 3, pp. 234-e6, 2014.
97. E. Perez-Gomez, C. Andradas, and S. Blasco-Benito, "Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer, " JNCI: Journal of the National Cancer Institute, vol. 107, no. 6, 2015.
98. C. A. Dumitru, I. E. Sandalcioglu, and M. Karsak, "Cannabinoids in Glioblastoma Therapy: New Applications for Old Drugs, " Frontiers in Molecular Neuroscience, vol. 11, article 159, 2018.
99. C. K. Jung, W. K. Kang, J. M. Park et al., "Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer, " Oncology Letters, vol. 5, no. 3, pp. 870-876, 2013.
100. F. K. Engels, F. A. de Jong, R. H. J. Mathijssen, J. A. Erkens, R. M. Herings, and J. Verweij, "Medicinal cannabis in oncology, " European Journal of Cancer, vol. 43, no. 18, pp. 2638-2644, 2007.
101. A. E. Munson, L. S. Harris, M. A. Friedman, W. L. Dewey, and R. A. Carchman, "Antineoplastic Activity of Cannabinoids2, " JNCI: Journal of the National Cancer Institute, vol. 55, no. 3, pp. 597-602, 1975.
102. I. Galve-Roperh, C. Sanchez, M. L. Cortes, T. G. Del Pulgar, M. Izquierdo, and M. Guzman, "Anti-Tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation, " Nature Medicine, vol. 6, no. 3, pp. 313-319, 2000.
103. C. Sanchez, M. L. de Ceballos, T. Gomez del Pulgar et al., "Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor, " Cancer Res, vol. 61, pp. 5784-5789, 2001.
104. M. L. Casanova, C. Blazquez, J. Martinez-Palacio et al., "Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors, "The Journal of Clinical Investigation, vol. 111, no. 1, pp. 43-50, 2003.
105. C. Blazquez, A. Carracedo, L. Barrado et al., "Cannabinoid receptors as novel targets for the treatment of melanoma., " The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, vol. 20, no. 14, pp. 2633-2635, 2006.
106. A. Carracedo, M. Gironella, M. Lorente et al., "Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulumstress-related genes, " Cancer Research, vol. 66, no. 13, pp. 6748-6755, 2006.
107. F. Cianchi, L. Papucci, N. Schiavone et al., "Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells, " Clinical Cancer Research, vol. 14, no. 23, pp. 7691-7700, 2008.
108. M. Bifulco and V. Di Marzo, "Targeting the endocannabinoid system in cancer therapy: A call for further research, " Nature Medicine, vol. 8, no. 6, pp. 547-550, 2002.
109. M. Bifulco, C. Laezza, S. Pisanti, and P. Gazzerro, "Cannabinoids and cancer: Pros and cons of an antitumour strategy, " British Journal of Pharmacology, vol. 148, no. 2, pp. 123-135, 2006.
110. N. Freimuth, R. Ramer, and B. Hinz, "Antitumorigenic effects of cannabinoids beyond apoptosis, " The Journal of Pharmacology and Experimental Therapeutics, vol. 332, no. 2, pp. 336-344, 2010.
111. M. Sawzdargo, T. Nguyen, D. K. Lee et al., "Identification and cloning of three novel humanG protein-coupled receptor genes GPR52, ?GPR53 and GPR55: GPR55 is extensively expressed in human brain, " Brain Research, vol. 64, no. 2, pp. 193-198, 1999.
112. R. Fredriksson, M. C. Lagerstrom, L.-G. Lundin, and H. B. Schioth, "The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints, "Molecular Pharmacology, vol. 63, no. 6, pp. 1256-1272, 2003.
113. D. Leyva-Illades and S. DeMorrow, "OrphanGproteinreceptor GPR55 as an emerging target in cancer therapy and management, " Cancer Management and Research, vol. 5, no. 1, pp. 147-155, 2013.
114. C. M. Henstridge, N. A. Balenga, R. Schroder et al., "GPR55 ligands promote receptor coupling to multiple signalling pathways, " British Journal of Pharmacology, vol. 160, no. 3, pp. 604-614, 2010.
115. J. E. Lauckner, J. B. Jensen, H.-Y. Chen, H.-C. Lu, B. Hille, and K. Mackie, "GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibitsMcurrent, " Proceedings of the National Acadamy of Sciences of the United States of America, vol. 105, no. 7, pp. 2699-2704, 2008.
116. S. Oka, S. Kimura, T. Toshida, R. Ota, A. Yamashita, and T. Sugiura, "Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-Activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells, "The Journal of Biochemistry, vol. 147, no. 5, pp. 671-678, 2010.
117. C. Andradas, M. M. Caffarel, E. Perez-Gomez et al., "The orphanGprotein-coupled receptorGPR55 promotes cancer cell proliferation via ERK, " Oncogene, vol. 30, no. 2, pp. 245-252, 2011.
118. E. Perez-Gomez, C. Andradas, J. M. Flores et al., "The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas, " Oncogene, vol. 32, no. 20, pp. 2534-2542, 2013.
119. E. Ryberg, N. Larsson, S. Sjogren et al., "The orphan receptor GPR55 is a novel cannabinoid receptor, " British Journal of Pharmacology, vol. 152, no. 7, pp. 1092-1101, 2007.
120. A. Kapur, P. Zhao, H. Sharir et al., "Atypical responsiveness of the orphan receptorGPR55 to cannabinoid ligands, "TheJournal of Biological Chemistry, vol. 284, no. 43, pp. 29817-29827, 2009.
121. A. Shrivastava, P. M. Kuzontkoski, J. E. Groopman, and A. Prasad, "Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-Talk between Apoptosis and Autophagy, "Molecular CancerTherapeutics, vol. 10, no. 7, pp. 1161-1172, 2011.
122. X. Zhang, Y. Maor, J. F. Wang, G. Kunos, and J. E. Groopman, "Endocannabinoid-like N-Arachidonoyl serine is a novel proangiogenic mediator, " British Journal of Pharmacology, vol. 160, no. 7, pp. 1583-1594, 2010.
123. G. Santoni, V. Farfariello, and C. Amantini, "TRPV Channels in TumorGrowth and Progression, " in Transient Receptor Potential Channels, vol. 704 of Advances in Experimental Medicine and Biology, pp. 947-967, Springer Netherlands, Dordrecht, 2011.
124. R. Vennekens, G. Owsianik, and B. Nilius, "Vanilloid transient receptor potential cation channels: An overview, " Current Pharmaceutical Design, vol. 14, no. 1, pp. 18-31, 2008.
125. A. Peralvarez-Mar?n, P. Doñate-Macian, and R. Gaudet, "What do we know about the transient receptor potential vanilloid 2 (TRPV2) ion channel?" FEBS Journal, vol. 280, no. 21, pp. 5471-5487, 2013.
126. T. Bisogno, L. Hanus, L. De Petrocellis et al., "Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide, " British Journal of Pharmacology, vol. 134, no. 4, pp. 845-852, 2001.
127. N. Qin, M. P. Neeper, Y. Liu, T. L. Hutchinson, M. L. Lubin, and C. M. Flores, "TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root Ganglion neurons, " The Journal of Neuroscience, vol. 28, no. 24, pp. 6231-6238, 2008.
128. A. Ligresti, A. S. Moriello, K. Starowicz et al., "Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma, " The Journal of Pharmacology and Experimental Therapeutics, vol. 318, no. 3, pp. 1375-1387, 2006.
129. M. Flourakis and N. Prevarskaya, "Insights into Ca2+ homeostasis of advanced prostate cancer cells, " Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, vol. 1793, no. 6, pp. 1105-1109, 2009.
130. A. M. Bode, Y.-Y. Cho, D. Zheng et al., "Transient receptor potential type vanilloid 1 suppresses skin carcinogenesis, " Cancer Research, vol. 69, no. 3, pp. 905-913, 2009.
131. M. A. Rochester, N. Patel, B.W. Turney et al., "The type 1 insulinlike growth factor receptor is over-expressed in bladder cancer, " BJU International, vol. 100, no. 6, pp. 1396-1401, 2007.
132. C. Amantini, P. Ballarini, S. Caprodossi et al., "Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in anATM-dependentmanner, " Carcinogenesis, vol. 30, no. 8, pp. 1320-1329, 2009.
133. J. C. Arnold, P. Hone, M. L. Holland, and J.D. Allen, "CB2and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells, " Pharmacological Reports, vol. 64, no. 3, pp. 751-757, 2012.
134. M. Nabissi, M. B. Morelli, M. Santoni, and G. Santoni, "Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents, " Carcinogenesis, vol. 34, no. 1, pp. 48-57, 2013.
135. M. B. Morelli, M. Nabissi, C. Amantini et al., "The transient receptor potential vanilloid-2 cation channel impairs glioblastoma stem-like cell proliferation and promotes differentiation, " International Journal of Cancer, vol. 131, no. 7, pp. E1067-E1077, 2012.
136. S. D. McAllister, R. Murase, R. T. Christian et al., "Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis, " Breast Cancer Research and Treatment, vol. 129, no. 1, pp. 37-47, 2011.
137. J. Perk, A. Iavarone, and R. Benezra, "Id family of helix-loophelix proteins in cancer, " Nature Reviews Cancer, vol. 5, no. 8, pp. 603-614, 2005.